Regeneron sees Q4 EYLEA U.S. sales of $1.54B, REGEN-COV sales of $2.29B
Bill Oxford/iStock via Getty Images                 

Regeneron Pharmaceuticals (REGN
+0.4%)Â expects preliminary U.S. net product sales for EYLEA (aflibercept) Injection of ~$1.54B for Q4 and ~$5.79B for FY 2021.
U.S. net product sales of REGEN-COV (casirivimab and imdevimab) of ~$5.82B for FY 2021 and ~$2.29B for Q4.